223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience

被引：14

作者：

Boni, Giuseppe ^{[1
]}

Mazzarri, Sara ^{[1
]}

Cianci, Claudia ^{[2
]}

Galli, Luca ^{[2
]}

Farnesi, Azzurra ^{[2
]}

Borsatti, Eugenio ^{[3
]}

Bortolus, Roberto ^{[4
]}

Fratino, Lucia ^{[5
]}

Gobitti, Carlo ^{[4
]}

Lamaj, Elda ^{[5
]}

Ghedini, Pietro ^{[6
]}

Rizzini, Elisa Lodi ^{[6
]}

Massari, Francesco ^{[7
]}

Dionisi, Valeria ^{[8
]}

Fanti, Stefano ^{[6
]}

Volterrani, Duccio ^{[1
]}

Monari, Fabio ^{[8
]}

机构：

[1] Univ Hosp Pisa, Nucl Med Unit, Pisa, Italy

[2] Univ Hosp Pisa, Med Oncol Unit, Pisa, Italy

[3] CRO IRCCS, Nucl Med Unit, Aviano, PN, Italy

[4] CRO IRCCS, Radiotherapy Unit, Aviano, PN, Italy

[5] CRO IRCCS, Med Oncol Unit, Aviano, PN, Italy

[6] Univ Bologna, S Orsola Malpighi Univ Hosp, Nucl Med Unit, Bologna, Italy

[7] Univ Bologna, S Orsola Malpighi Univ Hosp, Med Oncol Unit, Bologna, Italy

[8] Univ Bologna, S Orsola Malpighi Univ Hosp, Radiotherapy Unit, Bologna, Italy

来源：

TUMORI JOURNAL | 2018年 / 104卷 / 02期

关键词：

Brachytherapy; hormone-refractory prostate cancer; neoplasm metastasis; radium; VISUAL ANALOG SCALE; CLINICAL-TRIALS; EAU GUIDELINES; OPEN-LABEL; RADIUM-223; RA-223-DICHLORIDE; RA-223; BIODISTRIBUTION; RECOMMENDATIONS; POPULATION;

D O I：

10.1177/0300891618765571

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Radium-223 (Ra-223) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Our retrospective observational study presents the first Italian experience on the efficacy and safety of Ra-223 therapy in routine clinical practice. Methods: A total of 83 patients with metastatic CRPC were treated with Ra-223 at 3 Italian centers between August 2013 and August 2016. Ra-223-chloride (55 kBq/kg) was administered every 4 weeks for a total of 6 cycles. Primary endpoints were OS and progression-free survival (PFS). Secondary endpoints included toxicity, pain evaluation using numeric rating scale (NRS), symptomatic skeletal-related events and biomarkers response. Results: Patients had a median age of 75 (range 53-89) years. The majority of men showed a Gleason score of 7, 8, or 9. Forty-one patients completed 6 treatment cycles; 33 stopped treatment before completing 6 cycles. Nine were still receiving therapy at the time of data collection. At the end of therapy, NRS pain scores significantly improved (p < .000001). OS was a mean of 10.1 months, while median OS had not been attained. According to Kaplan-Meier estimation, OS and PFS were 17.5 and 7.7 months, respectively. There was a significant correlation between OS and PFS with the number of Ra-223 cycles; patients receiving all 6 cycles experienced the major benefit from the therapy. Ra-223 was well-tolerated. Conclusions: Ra-223 alpha therapy is an important therapeutic option for men with CRPC and symptomatic skeletal metastases.

引用

页码：128 / 136

页数：9

共 24 条

[1] High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities? [J].